Skip to content

Ipamorelin

Clinical evidence

Growth hormone–releasing peptide (GHRP) that stimulates GH release with relatively selective action. Not medical advice; consult a provider.

How Ipamorelin works

Ipamorelin stimulates GH release via ghrelin receptor. Dosing and monitoring should be under a provider. Not a substitute for medical care.

Researched benefits

  • •May support GH pulse without strong appetite stimulation
  • •Research in body composition and recovery
  • •Shorter half-life than some GHRH analogs

What it is studied for

  • •Body composition and recovery in research
  • •Sleep and recovery in some protocols
  • •Often combined with CJC-1295 or sermorelin

Reported side effects and cautions

  • •Possible injection-site reactions
  • •GH-related effects; monitoring recommended
  • •Not for use in active cancer or certain conditions

Dosing protocol described in the literature

Dosage
200-500mcg
Frequency
1-2x daily (fasted)
Administration
Subcutaneous
Cycle
8-16 weeks

GH release & recovery

Work out the reconstitution for this dose →

Evidence rating: Clinical evidence

Studied in human clinical trials. Some compounds in this tier are approved medicines for specific indications and require a prescription.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Ipamorelin. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.